Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954448 | 0.83 | ALDH1A1 (0.35) | PREPALDH1A1HSD17B10DPP4CYP3A4 | |
| SCHEMBL4955392 | 0.78 | ALDH1A1 (0.37) | ALDH1A1HSD17B10ACE | |
| SCHEMBL15392569 | 0.75 | HPGD (0.37) | ALDH1A1HSD17B10 | |
| SCHEMBL29588126 | 0.72 | HTT (0.37) | FAPALDH1A1HSD17B10DPP4 | |
| SCHEMBL15414815 | 0.71 | RIPK1 (0.36) | ALDH1A1HSD17B10DPP4 | |
| SCHEMBL2732689 | 0.71 | HPGD (0.38) | ALDH1A1HSD17B10DPP4 | |
| SCHEMBL5856782 | 0.71 | CPN1 (0.36) | — | |
| SCHEMBL21293929 | 0.70 | DPP4 (0.40) | PREPFAPDPP4 | |
| SCHEMBL4955982 | 0.70 | BBOX1 (0.35) | PREPFAPDPP4 | |
| Hydrochloric Acid SCHEMBL895282 | 0.70 | RIPK1 (0.36) | ALDH1A1HSD17B10DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439226-B2 | Serine protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130883-A1 | Serine protease inhibitors | PRSS1, TASP1, METAP1 | LTA4H 1884/4885PREP 51/4885FAP 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.